NewLink Genetics DROPS 11% and 4 Stock Analyses Making Waves

Orexigen Therapeutics, Inc. (NASDAQ:OREX): According to Leerlink’s predictions, the approval of VIVUS’s (NASDAQ:VVUS) Qsymia is good for Orexigen because it demonstrates the commitment from the FDA to approve obesity drugs. The firm increased its price target for Orexigen from $10 to $12 and maintains an Outperform rating on the stock. The firm predicts that there will be near-term trading volatility in Arena Pharmaceuticals (NASDAQ:ARNA) and recommends focusing on Orexigen’s upside.

Don’t Miss: Vivus VIVACIOUS! Second U.S. Diet Drug Approved in 13 Years.

Riverbed Technology, Inc. (NASDAQ:RVBD) is expected by William Blair to meet consensus estimates for Q2 following channel checks which suggested that the U.S. enterprise business for the company was stable during June as there was significant acceleration in the U.S. federal segment. William Blair still expects Riverbed to decrease guidance for the year’s second half and maintains a Market Perform rating on the stock.

F5 Networks, Inc. (NASDAQ:FFIV): According to William Blair, its enterprise checks for F5 have greatly improved this quarter compared to last, which the firm thinks should help the company meet consensus estimates for Q2. The firm sees a positive risk/reward for shares due to the negative sentiment and maintains an Outperform rating on the stock.

Wynn Resorts Ltd. (NASDAQ:WYNN) reported weaker-than-expected Q2 results, but Cantor still believes that company has substantial free cash flow potential, and a future upside from Cotai. The firm reiterates its Buy rating on the stock.

NewLink Genetics Corp’s (NASDAQ:NLNK) shares fell nearly 11 percent so far this quarter, but Cantor predicts a rebound in the stock. The firm remains bullish on the company’s technology and pipeline.

Don’t Miss: Is Apple Duping Its Portuguese Buyers?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.